The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 31, 2012
Filed:
Jun. 20, 2008
John J. Baldwin, Gwynedd Valley, PA (US);
Salvacion Cacatian, Blue Bell, PA (US);
David A. Claremon, Maple Glen, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
Alexey V. Ishchenko, Somerville, MA (US);
Lanqi Jia, Horsham, PA (US);
Gerard Mcgeehan, Garnet Valley, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Colin M. Tice, Ambler, PA (US);
Zhenrong Xu, Horsham, PA (US);
Jing Yuan, Lansdale, PA (US);
Wei Zhao, Eagleville, PA (US);
Linghang Zhuang, Chalfont, PA (US);
John J. Baldwin, Gwynedd Valley, PA (US);
Salvacion Cacatian, Blue Bell, PA (US);
David A. Claremon, Maple Glen, PA (US);
Lawrence W. Dillard, Yardley, PA (US);
Patrick T. Flaherty, Pittsburgh, PA (US);
Alexey V. Ishchenko, Somerville, MA (US);
Lanqi Jia, Horsham, PA (US);
Gerard McGeehan, Garnet Valley, PA (US);
Robert D. Simpson, Wilmington, DE (US);
Suresh B. Singh, Kendall Park, NJ (US);
Colin M. Tice, Ambler, PA (US);
Zhenrong Xu, Horsham, PA (US);
Jing Yuan, Lansdale, PA (US);
Wei Zhao, Eagleville, PA (US);
Linghang Zhuang, Chalfont, PA (US);
Vitae Pharmaceuticals, Inc., Fort Washington, PA (US);
Abstract
The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors.